Regione Veneto has awarded to Xeptagen a financial grant to sustain the extension of the clinical application of Hepa-IC to nonalcoholic steatohepatitis (NASH), by developing a mathematical model combining biomarker-IgMs and other physiological parameters to monitor patient evolution from steatosis to steatohepatitis and HCC. Nonalcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular carcinoma (HCC). As the most common form of chronic liver disease in developed countries, the prevalence of non alcoholic fatty liver disease (NAFLD), a precursor of NASH, in the US ranges from 20% to 46%, and the prevalence of NASH spans from 2% to 12%. Currently, there are no available biomarkers in the clinical practice to monitor NAFLD progression to NASH.